Maria Gili

photo seb


I am supporting the lab with a range of tasks. This starts at teaching new students molecular biology methods. Then I am routinely optimising recombinant protein production in different organisms and test protein purification buffers to enhance protein solubility. Furthermore I am generating expression vector systems to supply the lab flexible ressource for recombinant protein production.



Since January 2014: CRG, Cell and Developmental Biology. Research technician.
Project: Cytoskeleton dependent RNA distribution mechanisms.

2011 – 2013: CRG, Systems Biology department. Research technician.
Project: Building and characterisation of synthetic transcriptional networks in E. Coli.

March 2010 – September 2011. ERA Biotech. Technician in cell culture.

April 2007 – March 2010. “Institut de Recerca de la Vall d’Hebron”. Research technician.
Project: Study of treatment resistance in breast cancer Her2 positive.

June 2004 – March 2007. Institut de Recerca Oncològica(IRO) Research technician Research fellowship from “Red de centros de genética clínica y molecular”
Support research to Neurofibromatosis team.
Project:“Estudio genético, molecular y celular de neurofibromas”

April 2002 – 2004 Reference Laboratory (Barcelona). Molecular Biology Department. Technician. February – July 2001 “Università Di Firenze” (Italia). Molecular Anthropology Department.
Collaboration in a research project with the European Grant. Leonardo da Vinci



A unified design space of synthetic stripe-forming networks.
Y. Schaerli, A. Munteanu, M.Gili, J.Cotterell, J. Sharpe, M. Isalan,Nat Commun. 2014 Sep 23;5:4905. doi: 10.1038/ncomms5905.e

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.
Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. Nat Med. 2012 Feb 19;18(3):429-35. doi: 10.1038/nm.2619

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. Epub 2011 Feb 14.

PI3K Hyperactivation Results in Lapatinib Resistance that is Reversed by the mTOR/PI3K Inhibitor Bez235
Eichhorn P, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen R, Valero V, Seoane J, Bernards R, Baselga J. Cancer Res. 2008 Nov 15;68(22):9221-30.

Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients.
Serra E, Pros E, García C, López E, Gili ML, Gómez C, Ravella A, Capellá G, Blanco I, Lázaro C. Genes Chromosomes Cancer. 2007 Sep;46(9):820-7.

NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
Pros E, Larriba S, López E, Ravella A, Gili ML, Kruyer H, Valls J, Serra E, Lázaro C. Hum Mutat. 2006 Nov;27(11):1104-14.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s